PL3982963T3 - Kompozycja zawierająca pridopidynę i jej analog do leczenia choroby huntingtona i jej objawów - Google Patents
Kompozycja zawierająca pridopidynę i jej analog do leczenia choroby huntingtona i jej objawówInfo
- Publication number
- PL3982963T3 PL3982963T3 PL20823347.8T PL20823347T PL3982963T3 PL 3982963 T3 PL3982963 T3 PL 3982963T3 PL 20823347 T PL20823347 T PL 20823347T PL 3982963 T3 PL3982963 T3 PL 3982963T3
- Authority
- PL
- Poland
- Prior art keywords
- huntington
- analogue
- symptoms
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/438,508 US11090297B2 (en) | 2013-06-21 | 2019-06-12 | Pridopidine for treating huntington's disease |
| PCT/IL2020/050654 WO2020250234A1 (en) | 2019-06-12 | 2020-06-12 | Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3982963T3 true PL3982963T3 (pl) | 2026-03-16 |
Family
ID=73782137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20823347.8T PL3982963T3 (pl) | 2019-06-12 | 2020-06-12 | Kompozycja zawierająca pridopidynę i jej analog do leczenia choroby huntingtona i jej objawów |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20250352533A1 (pl) |
| EP (1) | EP3982963B1 (pl) |
| JP (2) | JP7436524B2 (pl) |
| CN (2) | CN113950328A (pl) |
| AU (1) | AU2020293739B2 (pl) |
| BR (1) | BR112021024744A2 (pl) |
| CA (1) | CA3137633A1 (pl) |
| CL (1) | CL2021003312A1 (pl) |
| DK (1) | DK3982963T3 (pl) |
| EA (1) | EA202193190A1 (pl) |
| ES (1) | ES3060357T3 (pl) |
| FI (1) | FI3982963T3 (pl) |
| HR (1) | HRP20260072T1 (pl) |
| IL (1) | IL288940B1 (pl) |
| LT (1) | LT3982963T (pl) |
| MX (1) | MX2021015338A (pl) |
| PL (1) | PL3982963T3 (pl) |
| PT (1) | PT3982963T (pl) |
| RS (1) | RS67638B1 (pl) |
| SM (1) | SMT202600016T1 (pl) |
| WO (1) | WO2020250234A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019015000A2 (pt) | 2017-01-20 | 2020-04-07 | Prilenia Neurotherapeutics Ltd. | uso de pridopidina para o tratamento da síndrome do x frágil |
| US20230390272A1 (en) * | 2020-10-20 | 2023-12-07 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine and analogs for the treatment of anxiety and depression |
| WO2025041080A1 (en) * | 2023-08-22 | 2025-02-27 | Philera New Zealand Ltd. | Selenium deficiency analysis and treatments |
| WO2025181805A1 (en) * | 2024-02-27 | 2025-09-04 | Prilenia Neurotherapeutics Ltd. | Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof |
| WO2025264449A1 (en) | 2024-06-20 | 2025-12-26 | Ptc Therapeutics, Inc. | Treatment of huntington's disease |
| CN118649245A (zh) * | 2024-08-16 | 2024-09-17 | 北京市疾病预防控制中心 | 聚乙烯吡咯烷酮修饰的钯纳米颗粒在制备治疗亨廷顿舞蹈症的产品中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| MX347209B (es) * | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| WO2014052933A1 (en) * | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| US20140088145A1 (en) * | 2012-09-27 | 2014-03-27 | Teva Pharmaceutical Industries, Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| DK3010506T3 (da) * | 2013-06-21 | 2021-07-12 | Prilenia Neurotherapeutics Ltd | Pridopidin i behandling af huntingtons sygdom |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| TW201618760A (zh) * | 2014-11-05 | 2016-06-01 | 雷普特製藥有限公司 | 使用半胱胺組合物治療亨廷頓氏病之方法 |
| DK3504187T3 (da) * | 2016-08-24 | 2025-04-14 | Prilenia Neurotherapeutics Ltd | Anvendelse af pridopidin til behandling af funktionel tilbagegang |
-
2020
- 2020-06-12 AU AU2020293739A patent/AU2020293739B2/en active Active
- 2020-06-12 CA CA3137633A patent/CA3137633A1/en active Pending
- 2020-06-12 MX MX2021015338A patent/MX2021015338A/es unknown
- 2020-06-12 ES ES20823347T patent/ES3060357T3/es active Active
- 2020-06-12 JP JP2021572628A patent/JP7436524B2/ja active Active
- 2020-06-12 PT PT208233478T patent/PT3982963T/pt unknown
- 2020-06-12 LT LTEPPCT/IL2020/050654T patent/LT3982963T/lt unknown
- 2020-06-12 HR HRP20260072TT patent/HRP20260072T1/hr unknown
- 2020-06-12 EA EA202193190A patent/EA202193190A1/ru unknown
- 2020-06-12 CN CN202080041805.4A patent/CN113950328A/zh active Pending
- 2020-06-12 SM SM20260016T patent/SMT202600016T1/it unknown
- 2020-06-12 EP EP20823347.8A patent/EP3982963B1/en active Active
- 2020-06-12 CN CN202511276654.1A patent/CN121243170A/zh active Pending
- 2020-06-12 RS RS20260029A patent/RS67638B1/sr unknown
- 2020-06-12 WO PCT/IL2020/050654 patent/WO2020250234A1/en not_active Ceased
- 2020-06-12 FI FIEP20823347.8T patent/FI3982963T3/fi active
- 2020-06-12 PL PL20823347.8T patent/PL3982963T3/pl unknown
- 2020-06-12 DK DK20823347.8T patent/DK3982963T3/da active
- 2020-06-12 IL IL288940A patent/IL288940B1/en unknown
- 2020-06-12 BR BR112021024744A patent/BR112021024744A2/pt unknown
-
2021
- 2021-12-10 CL CL2021003312A patent/CL2021003312A1/es unknown
-
2023
- 2023-10-30 JP JP2023185630A patent/JP2024016113A/ja active Pending
-
2025
- 2025-08-03 US US19/289,056 patent/US20250352533A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3982963T (pt) | 2026-01-29 |
| EP3982963B1 (en) | 2025-11-12 |
| IL288940A (en) | 2022-02-01 |
| EP3982963A1 (en) | 2022-04-20 |
| RS67638B1 (sr) | 2026-02-27 |
| EA202193190A1 (ru) | 2022-03-24 |
| EP3982963A4 (en) | 2023-06-21 |
| LT3982963T (lt) | 2026-02-10 |
| AU2020293739B2 (en) | 2023-11-30 |
| MX2021015338A (es) | 2022-01-18 |
| JP7436524B2 (ja) | 2024-02-21 |
| ES3060357T3 (en) | 2026-03-26 |
| SMT202600016T1 (it) | 2026-03-09 |
| AU2020293739A1 (en) | 2021-12-16 |
| BR112021024744A2 (pt) | 2022-03-22 |
| FI3982963T3 (fi) | 2026-01-23 |
| CN121243170A (zh) | 2026-01-02 |
| US20250352533A1 (en) | 2025-11-20 |
| HRP20260072T1 (hr) | 2026-02-27 |
| CN113950328A (zh) | 2022-01-18 |
| IL288940B1 (en) | 2026-02-01 |
| JP2024016113A (ja) | 2024-02-06 |
| CL2021003312A1 (es) | 2022-08-26 |
| JP2022535929A (ja) | 2022-08-10 |
| WO2020250234A1 (en) | 2020-12-17 |
| NZ782528A (en) | 2025-05-02 |
| DK3982963T3 (da) | 2026-01-19 |
| CA3137633A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3924481A4 (en) | Compositions and methods for treating hemoglobinopathies | |
| EP3755805A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF NON-AGE-RELATED HEARING DAMAGE IN AN INDIVIDUAL | |
| IL288940A (en) | Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof | |
| ZA202110597B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| MX2021002322A (es) | Nuevos metodos. | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| IL281809A (en) | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| EP3829628C0 (en) | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF C5-RELATED DISEASE | |
| GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| EP3850794A4 (en) | OUT OF STOCK FRONT-HAUL CONFIGURATION FOR C-RAN | |
| SG11202011296VA (en) | Compositions and methods for the treatment of parkinson's disease | |
| IL282562A (en) | Composition and use for the treatment of parkinson's disease and related disorders | |
| EP3892686A4 (en) | CURABLE ORGANOPOLYSILOXE COMPOSITION, CURED PRODUCT THEREOF, AND TRANSDUCER EQUIPPED WITH THE CURED PRODUCT AND THE LIKE | |
| GB201904373D0 (en) | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders | |
| EP3761419A4 (en) | ELECTRODE AND ELECTRODE ARRANGEMENT | |
| EP3996712A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF DEMENTIA WITH LEWY BODY | |
| EP3658157A4 (en) | TREATMENT OF HEART DISEASE BY INHIBITING THE EFFECT OF MUSCLE KINASE ANCHOR PROTEIN (MAKAP) | |
| EA202190097A1 (ru) | Композиция, содержащая аналог соматостатина, для радиофармацевтического применения | |
| IL285776A (en) | Useful preparations in the treatment of Kraba's disease | |
| ZA202101489B (en) | Compositions and methods for the treatment of parkinson's disease | |
| EP3941497A4 (en) | IMPROVED DECELLULARIZATION OF ISOLATED ORGANS | |
| IL285751A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| EP4642457A4 (en) | PRIDOPIDINE FOR THE TREATMENT OF JUVENILE HUNTINGTON'S DISEASE |